Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome.
Chorianopoulos
Emmanuel
E
Department of Cardiology, Angiology and Pulmology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany. e.chorianopoulos@med.uni-heidelberg.de
Jarr
Kai
K
Steen
Henning
H
Giannitsis
Evangelos
E
Frey
Norbert
N
Katus
Hugo A
HA
D000208:Acute Disease; D000368:Aged; D056988:Anterior Wall Myocardial Infarction / Q000503:physiopathology*; D003324:Coronary Artery Disease / Q000503:physiopathology; D000074049:Cytokine TWEAK; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010865:Pilot Projects; D011379:Prognosis; D012189:Retrospective Studies; D012307:Risk Factors; D016896:Treatment Outcome; D048069:Tumor Necrosis Factors / Q000097:blood*; D015854:Up-Regulation
D000074049:Cytokine TWEAK; C109743:TNFSF12 protein, human; D048069:Tumor Necrosis Factors